$6.78
N/A
Last update: Nov 5, 4:00 PM

Cartesian Therapeutics (RNAC) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-1.01 | $-0.68 | $-0.73 | $-0.80 |
| Actual | $-0.38 | $0.46 | $-1.46 | $-1.39 |
| Surprise | +62.4% | +167.7% | -100.0% | -73.8% |
| Revenue | ||||
| Estimate | $147144 | $162912 | $205912 | $212132 |
| Actual | $0 | $0 | $78000 | $947000 |
| Surprise | -100.0% | -100.0% | -62.1% | +346.4% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $-1.05 | $-1.13 | $-0.99 |
| Revenue | |||
| Consensus | $238568 | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $-0.38 | $-1.01 | 62.4 % |
| Q2 | Aug 6, 2026 | $0.46 | $-0.68 | 167.7 % |
| Q1 | Apr 30, 2026 | $-1.46 | $-0.73 | -100.0 % |
| Q4 | Mar 9, 2026 | $-1.39 | $-0.80 | -73.8 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $0 | $147.14K | -100.0 % |
| Q2 | Aug 6, 2026 | $0 | $162.91K | -100.0 % |
| Q1 | Apr 30, 2026 | $78.00K | $205.91K | -62.1 % |
| Q4 | Mar 9, 2026 | $947.00K | $212.13K | 346.4 % |